Inaphaea BioLabs

Pancreatic cancer is the 5th biggest cancer killer in the UK, with the lowest survival rate of all common cancers. At Inaphaea, we offer cells for purchase and testing services across our biobank of 470 Patient Derived Cancer cells, representing 66 types of cancer. These include 19 pancreatic cancer lines in our biobank, alongside 65 other indications. We are dedicated to comprehensively understanding our drug candidates during the discovery and preclinical phases of development and our goal is to support decision-making in translational drug development for therapeutic areas within oncology. View more on our website: https://www.inaphaea.com/ #PCAM #CancerResearch #DrugDevelopment #CancerAwareness #DrugDiscovery

We're pleased to announce that Inaphaea Director, Mark Eccleston has been appointed as a Non Executive Director for life sciences membership organisation Medilink Midlands. Medilink Midlands champions collaboration and innovation across the life sciences industry in the Midlands and beyond, and as members, we’re looking forward to seeing what new opportunities this partnership will bring. #LifeSciences #AssayDevelopment #Biotech #DrugDiscovery

In case you missed it, we recently released the latest in our company news roundups. In our latest edition, we share the latest news and insights from September and October. It has been a busy time for Inaphaea, with our parent company ValiRx signing several agreements with CROs and biotechs around the world as we move forward with our growth plans. We hope you enjoy the read and don't forget to subscribe: https://lnkd.in/ezDuZE2b #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch

Dr Mark Eccleston, CEO of our parent company, ValiRx is attending Oxford Global's Immuno US conference this week. Mark will be joining industry colleagues and business leaders in San Diego for two days of networking, discussions and presentations from expert speakers. If you'd like to book a meeting with Mark, get in contact: https://lnkd.in/dq5f2gy6 #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

Dr Mark Eccleston, CEO of our parent company, ValiRx is attending Oxford Global's Immuno US conference next week. Mark will be joining industry colleagues and business leaders in San Diego for two days of networking, discussions and presentations from expert speakers. If you'd like to book a meeting with Mark, get in contact: https://lnkd.in/dq5f2gy6 #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

Today VALIRX PLC will be hosting their Investor Presentation at 1pm BST. Click here to Register: https://lnkd.in/ePfA8XSv This is an exciting opportunity for current shareholders and potential investors to hear from ValiRx leadership team and engage in live Q&A.

Welcome to the Inaphaea newsletter, where we cover our latest news and updates from September and October. It has been a busy month for Inaphaea, with our parent company ValiRx signing several agreements with CROs and biotechs around the world as we move forward with our growth plans. Read more about the agreements in the newsletter below. We hope you enjoy the read and don't forget to subscribe. #Assays #AssayDevelopment #BioTech #DrugDiscovery #PDCs #CancerResearch #ScientificResearch

Meet the Inaphaea collaborator: Inspiralis Limited Inspiralis is a leading biotech specialising in DNA modifying enzymes and their substrates. The company supports preclinical development of anti-infective and anti-cancer compounds, either through the supply of its high-quality products or through the provision of contract research services in the form of drug screening and mode of action studies. In the latest of our collaborator blog series, we spoke to Natassja Bush, CEO at Inspiralis to find out more about the business, and its partnership with Inaphaea. Read the interview with Natassja here: https://bit.ly/486rAn0 #Collaboration #Assays #AssayDevelopment

Breast cancer is the most common cancer in the UK. October is Breast Cancer Awareness Month, which is dedicated to educating, raising awareness and supporting patients with breast cancer. At Inaphaea, we offer cells for purchase and testing services across our biobank of 470 Patient Derived Cancer cells, representing 66 types of cancer, including 23 breast cancer subtypes of which 3 are Triple Negative Breast Cancer. We are dedicated to comprehensively understanding our drug candidates during the discovery and preclinical phases of development to address the unique challenges of each subtype. Our goal is to support decision-making in translational drug development for therapeutic areas within oncology. View more on our website: https://bit.ly/3SINi9o #CancerResearch #DrugDevelopment #CancerAwareness #DrugDiscovery

Meet Inaphaea at the Oncology Venture, Innovation and Partnering Summit this week. As part of our plans to expand our reach and connect with potential customers around the world, the Inaphaea team is pleased to be attending the summit in Cambridge, Massachusetts. The summit provides delegates with the opportunity to connect with future investors and partners and gain strategic insights on funding activities and innovation strategies in cancer therapeutics and diagnostics. We are particularly looking forward to speaking to US businesses about Inaphaea's capabilities, which include our available 2D and 3D PDC models, alongside our immuno-oncology assays. Attending the summit is Inaphaea BioLabs' Director and CEO of parent company ValiRx, Dr Mark Eccleston. Mark is a polymer chemist and biotechnology entrepreneur with over 30 years of experience in drug and biomarker development. Mark will be in and around Boston from today. If you'd like to book a meeting, contact us here: https://lnkd.in/gjWnzYYe Cambridge VIP: Venture, Innovation & Partnering #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking #OncologyVIP